Nuwellis (NUWE)
Hospital ultrafiltration systems and disposable treatments for fluid overload.
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026.
Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a proven track record of advancing innovative products from concept through commercial launch.
Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications
Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapies Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapies
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patients Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patients
Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion into Wisconsin with the installation of its first Aquadex SmartFlow® systems at a leading pediatric healthcare institution. The installation further expands the Company's growing presence in pediatric critical care at one of the region's premier academic medical centers.
Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuwellis to report second quarter 2026 financial results on August 13 MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced unaudited preliminary results for its second quarter ended June 30, 2026, with revenue year-over-year growth of 14% for the second quarter of 2026 and 20% for the first six months of 2026. Management expects to report its financial results for the three and six months ended June 30, 2026, before the open of the U.S. financial markets on August 13th and will host a conference call and webcast beginning at 9:00 a.m.
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalities Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalities
Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026
MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its participation in the KidneyBee Summit 2026, taking place July 14-16, 2026, at Children's Hospital Colorado in Aurora, Colorado. As part of its participation, Nuwellis will engage with conference attendees to discuss the role of precise fluid management in pediatric patients with acute kidney injury, cardiorenal conditions, and fluid overload.
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4 ), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with leading pediatric cardiac critical care institutions to support clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Through these efforts, Nuwellis has helped foster dialogue around the growing clinical importance of fluid balance and the role of extracorporeal ultrafiltration therapies in pediatric intensive care settings.
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations
MINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion in Michigan with the installation of three Aquadex SmartFlow® systems at a leading pediatric healthcare provider. This represents Nuwellis' first pediatric program in the state of Michigan and further expands the Company's growing presence in pediatric critical care into a significant healthcare market.
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and outlines strategic priorities in a Letter to Shareholders from newly appointed CEO, Mike McCormick.
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit
MINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the clinical utility of its Aquadex SmartFlow® system at the 4th annual Critical Care Cardiology Education Summit (CCCES), hosted by the University of Minnesota. As part of the conference's skills-based curriculum, conference instructors conducted focused Aquadex training sessions that provided participants with practical experience using the Company's ultrafiltration technology.
Nuwellis Appoints Mike McCormick as Chief Executive Officer
Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's Hospitals
South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that already use the technology South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that already use the technology
Nuwellis Announces Pricing of $6 Million Public Offering
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a public offering of 20,000,000 shares of its common stock ("Common Stock") (or pre-funded warrants in lieu thereof) with accompanying warrants to purchase common stock for gross proceeds of approximately $6 million (the “Offering”).
Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label
Proposal would extend treatment access to pediatric patients weighing 5 kg and above Proposal would extend treatment access to pediatric patients weighing 5 kg and above
Nuwellis, Inc. (NUWE) Q1 2026 Earnings Call Transcript
Nuwellis, Inc. (NUWE) Q1 2026 Earnings Call Transcript